Zealand Pharma Presents New Preclinical Data on ZP2929 in Disease Models for Diabetes and Obesity

Zealand Pharma, a biopharmaceutical company based in Denmark, has presented new data from preclinical studies with ZP2929, a novel glucagon/GLP-1 dual agonist drug candidate in preclinical development for the treatment of Type 2 diabetes and obesity.
PharmaLive